Please login to the form below

Not currently logged in
Email:
Password:

Jakavi

This page shows the latest Jakavi news and features for those working in and with pharma, biotech and healthcare.

Lilly claims first place for JAK inhibitor Olumiant in EU

Lilly claims first place for JAK inhibitor Olumiant in EU

Another JAK inhibitor - Novartis' Jakavi/Jakafi (ruxolitinib) - is also on the market but is indicated for haematological cancers.

Latest news

More from news
Approximately 6 fully matching, plus 18 partially matching documents found.

Latest Intelligence

  • Back to the future Back to the future

    The successes of Gilenya, Afinitor/Votubia, Galvus, Tasigna and Jakavi - as well as its generics arm, Sandoz - mean that Novartis is now less than $500m behind Pfizer in second place.

  • Pharma deals during April 2014 Pharma deals during April 2014

    Jakavi (rare bone marrow disorder); Signifor (Cushing's disease) plus 16 products in 24 pivotal trials.

  • NICE and ‘ultra orphans’ NICE and ‘ultra orphans’

    Jakavi, in common with most orphan drugs, was assessed under NICE's existing arrangements, though also in common with rare disease treatments such as Roche's MabThera and Celgene's Revlimid, ... Indeed, producing its final guidance on Jakavi in June,

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Anthill is a specialist digital agency and a strategic partner for life science companies....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics